Compare LUNR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNR | ANAB |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2015 |
| Metric | LUNR | ANAB |
|---|---|---|
| Price | $10.62 | $48.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $29.00 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 6.7M | 465.6K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 84.23 | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | $210,059,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $337.87 | N/A |
| Revenue Next Year | $26.94 | $69.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $7.78 | $30.27 |
| 52 Week High | $46.75 | $73.30 |
| Indicator | LUNR | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 46.60 |
| Support Level | $10.04 | $44.38 |
| Resistance Level | $16.15 | $51.94 |
| Average True Range (ATR) | 0.78 | 2.32 |
| MACD | 0.08 | 0.47 |
| Stochastic Oscillator | 21.40 | 53.73 |
Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).